<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625102</url>
  </required_header>
  <id_info>
    <org_study_id>GHHBV-2-001</org_study_id>
    <nct_id>NCT03625102</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Randomized, Double-Blind, Dosing-Ranging, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golden Biotechnology Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Golden Biotechnology Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B virus infection is a worldwide disease and is still the most common cause of
      hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various
      side-effects including renal toxicity and drug resistance or failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B virus infection is a worldwide disease and is still the most common cause of
      hepatocellular carcinoma (HCC). Those carriers in China account for 33% of all chronic
      carriers globally. A big epidemiological study of patients with chronic hepatitis B has
      revealed that baseline HBV DNA level or cirrhosis is an independent predictor for the
      occurrence of HCC.

      Antroquinonol is a new chemical entity isolated from the mycelium of Antrodia camphorata,
      which showed interesting anticancer and anti-inflammatory activities.Previous studies have
      indicated that signaling molecules, such as PI3K, AMPK, and mTOR, participate in
      Antroquinonol-induced cancer cell death, whereas Nrf2 and NF-kB are involved in the
      anti-inflammatory effects of Antroquinonol. Moreover, we also found the administration of
      Antroquinonol also differentially modulated T cell activity and reduced IL-18 production, but
      enhanced the activation of Nrf2 and, thus, suppressed oxidative stress by animal studies.
      These results demonstrate the potential applications of Antroquinonol in treating hepatitis
      B.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single-center, phase IIa, double blind, and randomized, placebo-controlled trial of Antroquinonol in patients with hepatitis B infection. Subjects with diagnosis of hepatitis B meet inclusion/exclusion criteria will be randomized into 3 groups:
Antroquinonol 100 mg PO BID
Antroquinonol 50 mg PO BID
Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percentage improvement between baseline and day 85 in quantitative HBsAg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IU/mL</measure>
    <time_frame>4 week</time_frame>
    <description>Sserum hapatitis B virus DNA level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score</measure>
    <time_frame>12 week</time_frame>
    <description>The Fibrosis-4 score helps to estimate the amount of scarring in the liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unit/L</measure>
    <time_frame>4 week</time_frame>
    <description>Glutamic Oxaloacetic Transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unit /L</measure>
    <time_frame>4 week</time_frame>
    <description>Glutamic Pyruvic Transaminase</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>Antroquinonol 100 mg PO BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antroquinonol 50 mg PO BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule, 2 capsules placebo, twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antroquinonol</intervention_name>
    <description>Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.</description>
    <arm_group_label>Antroquinonol 100 mg PO BID</arm_group_label>
    <arm_group_label>Antroquinonol 50 mg PO BID</arm_group_label>
    <other_name>Hocena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects</description>
    <arm_group_label>Antroquinonol 50 mg PO BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic HBV infection patients between the ages of 20 and 75 years with serum
             hepatitis B surface antigen(HBsAg) positivity for more than 6 months

          2. BMI≦35

          3. HBsAg≧10 IU/mL and HBV DNA≧2000 IU/mL.

          4. AST or ALT≧25 IU and ALT&lt;5xULN

          5. Female subject must use effective methods of contraception.

          6. No abnormal finding of clinical relevance

          7. Written informed consent

        Exclusion Criteria:

          1. Evidence of hepatic decompensation such as:

               1. Coagulopathy defined as prolongation of prothrombin time greater than 3 seconds

               2. Total bilirubin of 2 times the upper limit of normal

               3. FIB-4 of 3.25 or greater

          2. Abnormal hematological and biochemical parameters at screening A、 White blood cell
             count less than 2500 cells/uL B、 Absolute neutrophil count (ANC) less than 1,000
             cells/mm3 (less than 750 mm3 for African or African-American subjects) C、 Hemoglobin
             less than 12 g/dL for males, less than 11 g/dL for females D、 Estimated GFR less than
             50 mL/min

          3. Suspected or confirmed liver diseases from etiologies other than HBV (such as alcohol,
             toxin, drug, shock, acute viral hepatitis A or E), co-infection with human
             immunodeficiency virus, hepatitis C virus or hepatitis delta virus, prior antiviral
             treatment with NUCs or interferon, and recent immunosuppressive therapy (including
             chemotherapy and systemic corticosteroid).

          4. Immunodeficiency disorders or severe autoimmune disease

          5. Severe pulmonary disorders or significant cardiac diseases

          6. Gastrointestinal disorder with post-operative condition that could interfere with drug
             absorption

          7. Significant psychiatric illness that in the judgment of the Investigator, is a
             contraindication to protocol participation or impairs a volunteer's ability to give
             informed consent

          8. Any malignancy diagnosed within 5 years or evidence of hepatocellular carcinoma (e.g.,
             α fetoprotein &gt; 50ng/mL or radiologic evidence)

          9. Solid organ transplantation

         10. Current drug or alcohol abuse

         11. Pregnancy or lactation

         12. Under hepatitis B antiviral or interferon treatment within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Pin Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pei-Ni Chen, MD</last_name>
    <phone>886-2-28086006</phone>
    <email>pnchen79@goldenbiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CHUN-CHUAN Chang</last_name>
    <phone>886-2-28086006</phone>
    <email>heroman@goldenbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Pin Lin, MD</last_name>
      <phone>886-4-24739595</phone>
    </contact>
    <contact_backup>
      <last_name>Hsuan-Yi Chen</last_name>
      <phone>886-4-24739595</phone>
      <email>circlerank@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antroquinonol</keyword>
  <keyword>Hocena</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

